CriticalTriptan, selective 5HT1B/1D receptor agonist×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
At recommended doses, selegiline inhibits monoamine oxidase type B (MAO-B) selectively and irreversibly, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Naratriptan stimulates serotonin 5-HT1B and 5-HT1D receptors, which take part in the constriction of intracranial blood vessels (naratriptan SmPC, AEMPS, section 5.1). The selegiline SmPC contraindicates its use with serotonin agonists, naratriptan among them, because of the risk of serious interactions that can lead to serotonin syndrome (AEMPS, section 4.5). The naratriptan documents give no data on higher naratriptan levels with monoamine oxidase (MAO) inhibitors. Naratriptan did not inhibit MAO in vitro, so no in vivo interaction studies with MAO inhibitors exist. The kidneys excrete half of the dose unchanged, and many cytochrome P450 enzymes take part in its limited metabolism (naratriptan SmPC, AEMPS, sections 4.5 and 5.2).
Symptoms
The prescribing information does not describe how this particular combination presents. However, the selegiline summary of product characteristics (SmPC) warns that serious interactions with serotonin agonists can lead to serotonin syndrome (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). With monoamine oxidase (MAO) inhibitors, serotonin syndrome may occur during naratriptan treatment: agitation, hallucinations, coma, fast heart rate, labile blood pressure, high temperature, overactive reflexes, poor coordination, nausea, vomiting and diarrhoea. It usually starts within minutes to hours of a new or higher dose of a serotonergic drug (naratriptan label, US Food and Drug Administration, FDA, section 5.7). Naratriptan itself can cause pain, heaviness, pressure or tightness in any part of the body, including the chest and throat, and these sensations are sometimes intense. Within 12 hours of a dose, blood pressure may rise by about 5 mmHg systolic and 3 mmHg diastolic (naratriptan SmPC, AEMPS, sections 4.4 and 4.8). On rare occasions triptans have caused a marked rise in blood pressure, up to hypertensive crisis with acute impairment of organ systems, including in people with no history of hypertension (FDA naratriptan label, section 5.8).
Management
The combination is contraindicated. The selegiline summary of product characteristics (SmPC) lists serotonin agonists among contraindicated combinations and names naratriptan (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The Spanish naratriptan SmPC and the US Food and Drug Administration (FDA) naratriptan label do not list monoamine oxidase (MAO) inhibitors among their contraindications, but the contraindication in the selegiline SmPC still applies. No document gives an interval between stopping selegiline and the first dose of naratriptan, or for the opposite switch. Selegiline inhibits MAO type B irreversibly, and after a single 10 mg dose platelet MAO-B activity returns to normal in about 2 weeks (selegiline SmPC, AEMPS, section 5.2). If the two drugs have nevertheless been taken together and signs of serotonin syndrome appear, stop naratriptan (FDA naratriptan label, section 5.7). Monitor blood pressure during naratriptan treatment (FDA naratriptan label, section 5.8). Naratriptan is contraindicated in moderate or severe hypertension and in uncontrolled mild hypertension (naratriptan SmPC, AEMPS, section 4.3). If chest pain and tightness suggest cardiac ischaemia, withhold further naratriptan doses and assess the patient (naratriptan SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Naratriptán (nº registro 61828), sección 4.3 (2023)– AEMPS, CIMA, nº registro 61828 (Naramig 2,5 mg, Glaxo), revisión 11/2023 (fecha del documento en CIMA; la sección 10 indica junio 2020), secciones 4.3, 4.4 y 4.5
- FDA: Naratriptan tablets, Bionpharma (naratriptan) prescribing information (2026)– FDA, DailyMed setid 93b7e6c2-e6a7-4f6b-9ecd-62d6bb0a6dda, revisión 06/2026 (versión 4), secciones 4, 5.1–5.8 y 7.1